REC-994
- Generic Name
- REC-994
- Drug Type
- Small Molecule
- Background
REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
Phase 2
Active, not recruiting
- Conditions
- Cerebral Cavernous Malformation
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Recursion Pharmaceuticals Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT05085561
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Xenoscience Inc, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath